Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2025-11-17 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of an analyst/institutional investor meeting. It references an earnings deck for Q2 FY26 that was previously uploaded on October 31, 2025, but does not contain any financial data or detailed report itself. The document is an intimation under SEBI regulations about the meeting schedule, not the earnings release or the full report. The length is only 1717 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and intimation.
2025-11-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings call for the quarter and half year ended September 30, 2025, for Strides Pharma Science Limited. It includes management commentary on financial results, business performance, growth metrics, profitability, and outlook. The text explicitly mentions it is a transcript of the earnings call, with detailed discussion of quarterly and half-year financial results, including revenue, EBITDA, PAT, margins, and market performance. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters, indicating it is a full transcript rather than a brief announcement or summary. Therefore, the correct classification is CT (Call Transcript) with high confidence.
2025-11-05 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of un-audited financial results for the quarter and half year ended September 30, 2025. It mentions that the results are published as a newspaper advertisement and are also available on the company's website. The document itself is short (1765 characters) and serves as a notification or announcement rather than containing the full financial report or detailed financial data. Therefore, it is not the Interim/Quarterly Report itself but an announcement of the publication of such results. According to the rules, such a document should be classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial data or the full report.
2025-11-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 70% confidence The document is a letter addressed to stock exchanges informing about the availability of the audio recording of an earnings call discussing unaudited financial results for the quarter and half year ended September 30, 2025. It references the earnings call and provides a link to the audio recording, but does not contain the transcript itself or detailed financial data. The document length is short (1548 characters) and serves as an announcement of the earnings call recording availability rather than the call transcript itself. According to the classification rules, announcements about earnings calls or their recordings are best classified as Call Transcript (CT) if the full transcript is provided, but since this is only an announcement of the audio recording availability, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement without the actual transcript or financial data. However, given the options and the nature of the document, the closest specific category is Call Transcript (CT) because it pertains directly to the earnings call content, but since the transcript is not included, confidence is moderate.
2025-10-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges informing them about the availability of the audio recording of an earnings call discussing unaudited financial results for the quarter and half year ended September 30, 2025. It references the earnings call and provides a link to the audio recording but does not contain the transcript or the financial results themselves. The document length is short (1472 characters), and it serves as an announcement of the earnings call recording availability rather than the transcript or the earnings release itself. According to the filing definitions, a full text transcript of the earnings call is classified as Call Transcript (CT), but this document only announces the availability of the audio recording, not the transcript. It is not an earnings release (ER) because it does not contain financial highlights or results. Given the nature of the document, it best fits the Call Transcript (CT) category as it pertains directly to the earnings call content, even though it is an announcement of the audio recording. The confidence is high because the document explicitly mentions the earnings call and the audio recording related to financial results for a specific quarter and half year period.
2025-10-31 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated October 31, 2025, announcing the consolidated financial results for the quarter Q2FY26 and half year H1FY26 ended September 30, 2025. It includes detailed financial highlights such as revenue, gross margin, EBITDA, operational PAT, and EPS, along with commentary from the MD & Group CEO. The document also contains an earnings presentation with charts and business outlook. The content is comprehensive and includes actual financial data and analysis for the quarter and half year, which is characteristic of an Interim / Quarterly Report. It is not merely an announcement or a brief earnings release but a detailed report with substantive financial information. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-10-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.